Page 16 - Read Online

of control of large tumors. The effectiveness of RFA Conflicts of interest
depends on thermal necrosis and blood flow through the There are no conflicts of interest.
tumor promotes heat loss and prevents proper heating
of the tumor. A strategy of combining TACE with RFA REFERENCES
by performing TACE before RFA treatment to reduce 1. Kew MC. Epidemiology of hepatocellular carcinoma. Toxicology
the heat-sink effect and increase the ablation volume 2002;181-182:35-8.
of the tumor was recently evaluated in a randomized 2. Liver Cancer Study Group of Japan. Primary liver cancers in Japan.
[74]
study. In this study, patients with tumors larger than 3 3. Cancer 1980;45:2663-9.
Lai EC, Fan ST, Lo CM, Chu KM, Liu CL, Wong J. Hepatic resection
cm were randomized to TACE, RFA, and TACE-RFA. The for hepatocellular carcinoma. An audit of 343 patients. Ann Surg
combination modality was superior in median survival 1995;221:291-8.
(TACE-RFA at 37 months, TACE at 24 months vs. RFA at 22 4. Alsowmely AM, Hodgson HJ. Non-surgical treatment of
hepatocellular carcinoma. Aliment Pharmacol Ther 2002;16:1-15.
months) and rate of objective tumor response (TACE-RFA 5. Otto G, Heuschen U, Hofman WJ, Krumm G, Hinz U, Herfarth
at 54%, TACE at 35% vs. RFA at 36%). The positive findings C. Survival and recurrence after liver transplantation versus liver
in this study represent initial evidence in support for the resection for hepatocellular carcinoma: a retrospective analysis. Ann
Surg 1998;227:424-32.
use of combining local regional modalities to improve 6. Llovet JM, Fuster J, Bruix J. Intention-to-treat analysis of surgical
outcomes in patients with unresectable tumors. Despite treatment for early hepatocellular carcinoma: resection versus
aggressive local treatments with this combinational transplantation. Hepatology 1999;30:1434-40.
strategy, recurrence, and distant metastasis continue to 7. Dyon D, Mouzon A, Jourde AN, Regensberg C, Frileux C. Hepatic,
arterial embolization in patients with malignant liver tumours. Ann
have a significant effect on the overall survival of patients Radiol (Paris) 1974;17:593-603. (in French)
with HCC. Therefore, studies that combine effective 8. Llovet JM, Bruix J. Systematic review of randomized trials for
systemic treatment such as sorafenib with either TACE unresectable hepatocellular carcinoma: chemoembolization improves
survival. Hepatology 2003;37:429-42.
or RFA have the potential of further improving treatment 9. Takayasu K, Shima Y, Muramatsu Y, Moriyama N, Yamada
outcomes. Although the combination of RFA and TACE T, Makuuchi M, Hasegawa H, Hirohashi S. Hepatocellular
is most commonly used, TACE has also been combined carcinoma: treatment with intra-arterial iodized oil with and without
chemotherapeutic agents. Radiology 1987;163:345-51.
with interstitial laser photocoagulation, microwave 10. Sumie S, Yamashita F, Ando E, Tanaka M, Yano Y, Fukumori
coagulation, ethanol injection, or HIFU. [73,75,76] On the K, Sata M. Interventional radiology for advanced hepatocellular
other hand, the combination of TACE and immunotherapy carcinoma: comparison of hepatic artery infusion chemotherapy
and transcatheter arterial lipiodol chemoembolization. AJR Am J
or anti-angiogenesis therapy could also be an attractive Roentgenol 2003;181:1327-34.
field for future clinical application. 11. Lin SC, Shih SC, Kao CR, Chou SY. Transcatheter arterial
embolization treatment in patients with hepatocellular carcinoma and
risk of pulmonary metastasis. World J Gastroenterol 2003;9:1208-11.
CONCLUSION 12. A comparison of lipiodol chemoembolization and conservative
treatment for unresectable hepatocellular carcinoma. Groupe d’Etude
Image-guided transcatheter and ablative approaches et de Traitement du Carcinome Hépatocellulaire. N Engl J Med
1995;332:1256-61.
currently play an important role in the management of 13. Llovet JM, Real MI, Montaña X, Planas R, Coll S, Aponte J, Ayuso
patients with HCC, a role that is likely to grow even more C, Sala M, Muchart J, Solà R, Rodés J, Bruix J; Barcelona Liver
given the rapid pace of evolution in these technologies. Cancer Group. Arterial embolisation or chemoembolisation versus
In selected patient populations, these approaches already symptomatic treatment in patients with unresectable hepatocellular
carcinoma: a randomized controlled trial. Lancet 2002;359:1734-9.
offer survival rates that are comparable to that of surgery, 14. Lo CM, Ngan H, Tso WK, Liu CL, Lam CM, Poon RT, Fan ST,
with the added benefits of reduced morbidity and costs, Wong J. Randomized controlled trial of transarterial lipiodol
improved quality of life and shortened recovery time. chemoembolization for unresectable hepatocellular carcinoma.
Hepatology 2002;35:1164-71.
As the management of patients with HCC continues to 15. Uraki J, Yamakado K, Nakatsuka A, Takeda K. Transcatheter hepatic
evolve toward disease containment rather than a cure arterial chemoembolization for hepatocellular carcinoma invading
and locoregional targeted therapy rather than systemic the portal veins: therapeutic effects and prognostic factors. Eur J
Radiol 2004;51:12-8.
approaches, image-guided techniques pose as perfectly 16. Brown KT, Nevins AB, Getrajdman GI, Brody LA, Kurtz RC, Fong
suited methods for this direction. Results from clinical trials Y, Blumgart LH. Particle embolization for hepatocellular carcinoma.
involving such approaches are increasingly promising, and J Vasc Interv Radiol 1998;9:822-8.
the potential for improvement remains vast. As a result, 17. Cammà C, Schepis F, Orlando A, Albanese M, Shahied L, Trevisani
F, Andreone P, Craxì A, Cottone M. Transarterial chemoembolization
these therapeutic approaches will undoubtedly positively for unresectable hepatocellular carcinoma: meta-analysis of
impact the outcomes of patients with HCC. randomized controlled trials. Radiology 2002;224:47-54.
18. Bruix J, Llovet JM, Castells A, Montañá X, Brú C, Ayuso MC,
Vilana R, Rodés J. Transarterial embolization versus symptomatic
Financial support and sponsorship treatment in patients with advanced hepatocellular carcinoma: results
Nil. of a randomized, controlled trial in a single institution. Hepatology

Hepatoma Research | Volume 2 | Issue 1 | January 15, 2016 7